The Gynecologic Oncology Group (GOG) is the foremost multidisciplinary cooperative clinical trial research group devoted to the study of gynecologic malignancies. Since its inception in 1970, the GOG has been a recognized leader in the development of new forms of treatment and has relied on Phase III trials as the design to identity new standards of care for cancers of the female genital tract, in particular ovarian carcinoma, carcinoma of the uterine cervix, and endometrial carcinoma. Supporting that major activity are the concerted efforts of special studies committees focusing on translational research, developmental therapeutics, quality of life, and cancer prevention and control;and modality committees providing recent approaches and procedures in each of the relevant diagnostic and therapeutic disciplines. The GOG has an active, effective program in the study of new surgical and radiation approaches as well as new systemic agents. In patients with advanced ovarian cancers, GOG studies have defined the current standard of care of cytoreductlve surgery followed by systemic therapy including a taxane and a platinum compound. Current studies seek to improve on this standard with trials of intraperitoneal therapy, targeted agents, and maintenance therapy for those in complete remission. In patients with carcinoma of the cervix, GOG studies have identified new chemotherapeutic agents and combinations for use in the setting of advanced or recurrent disease and have set the standard of care for earlier stage cervix cancer (FIGO stages IB-IVA) as concurrent, cisplatin-based chemoradiation. Current and planned investigations will explore better chemoradiation combinations and the role of targeted agents such as bevacizumab. In patients with endometrial carcinoma, GOG studies have changed the paradigm for the management of advanced or recurrent disease by defining roles for chemotherapy in this difficult patient population. The GOG also has an active effort in less common gynecologic malignancies including uterine sarcomas, gestational trophoblastic disease, germ cell tumors of the ovary, vulvar cancer, among others. Making all of this effort to improve the standard of care possible is an active and extensive effort to identity new approaches through developmental therapeutics and to develop a better understanding of the biology of these malignancies through an active and extensive translational research program. After more than 39 years, the GOG continues to be foremost in developing new strategies for managing these cancers.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Gynecologic Oncology Group
United States
Zip Code
Reyes, Henry D; Thiel, Kristina W; Carlson, Matthew J et al. (2014) Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers. Mol Diagn Ther 18:137-51
Powell, Matthew A; Sill, Michael W; Goodfellow, Paul J et al. (2014) A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study. Gynecol Oncol 135:38-43
Fleming, Gini F; Filiaci, Virginia L; Marzullo, Brandon et al. (2014) Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 132:585-92
Kang, Le; Carter, Randy; Darcy, Kathleen et al. (2013) A fast Monte Carlo EM algorithm for estimation in latent class model analysis with an application to assess diagnostic accuracy for cervical neoplasia in women with AGC. J Appl Stat 40:2699-2719
Abrams, Jeffrey S; Mooney, Margaret M; Zwiebel, James A et al. (2013) Implementation of timeline reforms speeds initiation of National Cancer Institute-sponsored trials. J Natl Cancer Inst 105:954-9
Engler, David A; Gupta, Sumeet; Growdon, Whitfield B et al. (2012) Genome wide DNA copy number analysis of serous type ovarian carcinomas identifies genetic markers predictive of clinical outcome. PLoS One 7:e30996
Dewdney, Summer B; Kizer, Nora T; Andaya, Abegail A et al. (2012) Uterine serous carcinoma: increased familial risk for lynch-associated malignancies. Cancer Prev Res (Phila) 5:435-43
Kunos, Charles A; Sill, Michael W; Buekers, Thomas E et al. (2011) Low-dose abdominal radiation as a docetaxel chemosensitizer for recurrent epithelial ovarian cancer: a phase I study of the Gynecologic Oncology Group. Gynecol Oncol 120:224-8
Liao, S-Y; Rodgers, W H; Kauderer, J et al. (2011) Carbonic anhydrase IX (CA-IX) and high-risk human papillomavirus (H-HPV) as diagnostic biomarkers of cervical dysplasia/neoplasia in Japanese women with a cytologic diagnosis of atypical glandular cells (AGC): a Gynecologic Oncology Group (GOG) Study. Br J Cancer 104:353-60
He, X; Arslan, A D; Pool, M D et al. (2011) Knockdown of splicing factor SRp20 causes apoptosis in ovarian cancer cells and its expression is associated with malignancy of epithelial ovarian cancer. Oncogene 30:356-65

Showing the most recent 10 out of 339 publications